Last reviewed · How we verify
NCT06984705
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)
trial in Mpox (Monkeypox) in 144 participants. Enrolling by invitation.
31 July 2025
Quick facts
| Lead sponsor | Osaka Metropolitan University |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 144 |
| Start date | 31 July 2025 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across Democratic Republic of the Congo |
Conditions studied
- Mpox (Monkeypox) — all drugs for Mpox (Monkeypox) →
Sponsor
Osaka Metropolitan University
Who can join
Eligibility, any sex, with Mpox (Monkeypox). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate the effectiveness of smallpox vaccination administered before the global eradication of smallpox against currently circulating mpox in the Democratic Republic of the Congo. The main question it aims to answer is: Is the smallpox vaccine experience protective against mpox infection ? Researchers will compare mpox test positive group and negative group to see if the smallpox vaccine can protect against mpox infection. Participants will * be included after informed consent, * respond the survey with structured questionnaire * and accept skin lesion and blood sampling.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06984705
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mpox (Monkeypox)
Currently open trials in the same condition.
- NCT07267390 — Investigating MPXV Viral Clearance in Mpox Cases and Secondary Attack Rate in Contacts · recruiting
- NCT06839989 — An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa · Phase 2 · recruiting
- NCT06353737 — Looking for Asymptomatic Mpox in a Population at High Risk · recruiting
Other Osaka Metropolitan University trials
Trials by the same sponsor.
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
- NCT07067723 — Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of C · enrolling by invitation
- NCT07055867 — Epidemiological and Clinical Characteristics of Mpox Outbreak in Equateur, the DR Congo (Part1) · enrolling by invitation
- NCT06432543 — Polyethylene Wear Particle Analysis of THA · recruiting
- NCT06426641 — Polyethylene Wear Particle Analysis of TKA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06984705 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Osaka Metropolitan University
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06984705.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing